Lv2
160 积分 2022-02-24 加入
Targeting the FGFR Pathway in Patients with Advanced Solid Tumors
1个月前
已完结
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
1个月前
已完结
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
1个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
1个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
2个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
2个月前
已完结
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
2个月前
已完结
Pharmacological targeting of the cancer epigenome
2个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
2个月前
已完结
皖公网安备34019202002308
